Exenatide (Exendin-4) — what it does, evidence, and safety

What it is

Exenatide is a synthetic version of exendin-4, a peptide first isolated from Gila monster venom, and was the first GLP-1 medicine ever approved by the FDA (2005) for type 2 diabetes. It works the same way as later GLP-1 drugs, copying a gut hormone involved in fullness and blood-sugar control, and was sold as Byetta (twice-daily injection) and Bydureon (once-weekly injection); it was never FDA-approved for obesity. Both branded products have since been discontinued, and the FDA withdrew their approvals in 2025.

What the research found

Exenatide was a GLP-1 injection FDA-approved for type 2 diabetes (its branded products have since been discontinued). In the trials supporting approval it improved blood-sugar control (HbA1c) in adults with type 2 diabetes, and a large cardiovascular outcomes trial (EXSCEL) found it non-inferior to placebo for major heart events. It has been largely replaced in practice by newer GLP-1 medicines with stronger blood-sugar and weight effects. The research attributes these weight and blood-sugar changes largely to reduced appetite and food intake (greater satiety via the gut-hormone pathway these agents act on), an appetite and energy-intake mechanism measured across the trials.

Status and regulatory position

Both branded products discontinued; FDA approvals withdrawn. Exenatide was the first FDA-approved GLP-1 receptor agonist — Byetta (exenatide twice-daily injection, NDA 021773, originally approved April 28, 2005, Amylin Pharmaceuticals / Eli Lilly) and Bydureon / Bydureon BCise / Bydureon Pen (exenatide extended-release once-weekly injection, NDA 022200, originally approved January 27, 2012, Amylin / Alkermes / AstraZeneca; BCise autoinjector 2017; pediatric T2DM ≥10 years 2021). AstraZeneca discontinued both branded products in October 2024, and the FDA withdrew both NDAs (021773 and 022200) effective September 3, 2025 (Federal Register Vol. 90, No. 147, August 4, 2025, doc 2025-14683).[⁷] A generic twice-daily exenatide pen (Amneal Pharmaceuticals; FDA-approved November 19, 2024, launched 2025) is now the only exenatide product marketed in the US — the once-weekly extended-release formulation is no longer available.[⁸] The extended-release Bydureon formulation used 50:50 poly(D,L-lactide-co-glycolide) (PLGA) microspheres for sustained release across the weekly dosing interval. Exenatide's indication history is exclusively type 2 diabetes mellitus (T2DM) as adjunct to diet and exercise — not FDA-approved for obesity (unlike the modern GLP-1 family entries Wegovy/semaglutide and Zepbound/tirzepatide which carry separate obesity indications). Black-box warning on the Bydureon label for thyroid C-cell tumors (based on rat/mouse carcinogenicity) — same class warning as semaglutide, tirzepatide, and liraglutide. Not DEA-scheduled. Not listed on the WADA 2026 Prohibited List — consistent with the entire GLP-1 family being absent from WADA listings.[⁶]

Safety

Exenatide is a prescription-only medication, FDA-approved only for type 2 diabetes, and carries a class boxed warning related to thyroid C-cell tumors. It is not on the WADA Prohibited List. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

Disclosures

⚠️ For research and educational purposes only. Exenatide was FDA-approved as Byetta (twice-daily) and Bydureon / Bydureon BCise (once-weekly) for type 2 diabetes, but all branded exenatide products are discontinued and their approvals were withdrawn — the FDA Orange Book lists BYETTA, BYDUREON, bydureon pen and bydureon bcise as discontinued. The only exenatide product it lists as marketed is a generic (Amneal, ANDA 206697). There is no currently-marketed branded exenatide. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ First FDA-approved GLP-1 receptor agonist (April 28, 2005) — the regulatory-history anchor for the entire incretin-mimetic class. Exenatide / Byetta opened the GLP-1 ra pharmaceutical category with FDA approval for T2DM in April 2005, predating liraglutide (Victoza FDA-approved 2010 / Saxenda 2014), semaglutide (Ozempic 2017 / Wegovy 2021 / Rybelsus 2019), tirzepatide (Mounjaro 2022 / Zepbound 2023), and retatrutide (Phase 3, not yet approved). Largely supplanted by semaglutide and tirzepatide in modern T2DM and obesity practice because (a) once-weekly semaglutide produces stronger HbA1c reduction with similar safety profile; (b) tirzepatide's dual GLP-1/GIP agonism produces stronger weight loss; (c) semaglutide and tirzepatide carry FDA-approved obesity indications that exenatide does not. Exenatide remains the foundational GLP-1 ra citation for regulatory and clinical-history context — researchers entering the GLP-1 family literature need to understand that exenatide is the parent compound from which the entire modern GLP-1 ra pharmaceutical class derives.

⚠️ Byetta vs Bydureon — two distinct exenatide formulations with substantially different pharmacology. This is the load-bearing formulation distinction: - Byetta (exenatide twice-daily injection) — original 2005 product. or subcutaneous twice daily, within 60 minutes before morning and evening meals. Plasma half-life ~2.4 hours. Higher peak/trough variation; tighter postprandial glucose control; more nausea (especially in first 4 weeks); requires twice-daily injection adherence. - Bydureon / Bydureon BCise / Bydureon Pen (exenatide extended-release once weekly) — 2012 follow-up product. subcutaneous once weekly. Uses 50:50 poly(D,L-lactide-co-glycolide) (PLGA) microspheres for sustained release across the weekly dosing interval. Effective half-life ~7 days (controlled by the microsphere release profile, not the parent peptide PK). Lower peak/trough variation; smoother glycemic control; substantially less nausea than Byetta; once-weekly dosing aligns with semaglutide and dulaglutide. Modern clinical practice favors Bydureon over Byetta when exenatide is selected, due to the better tolerability profile and once-weekly dosing convenience. However, both are now substantially less prescribed than semaglutide (Ozempic) and tirzepatide (Mounjaro) — exenatide's commercial position has declined as the newer GLP-1 RAs displaced it. Generic exenatide twice-daily is available since 2017 patent expiration.

⚠️ FDA black-box warning for thyroid C-cell tumors — same class warning as the rest of the modern GLP-1 family. The Bydureon FDA label carries a black-box warning for risk of thyroid C-cell tumors based on findings of C-cell adenomas and C-cell carcinomas in rats and mice exposed to exenatide extended-release at all doses in 2-year carcinogenicity studies. Human relevance is unknown but the label-level concern is a class effect across the GLP-1 ra family (semaglutide, tirzepatide, and liraglutide all carry similar boxed warnings). Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Additional important safety considerations: acute pancreatitis (class effect; case reports + theoretical concern), acute kidney injury (volume depletion from GI side effects; particular concern in patients with pre-existing renal impairment), hypoglycemia (when combined with sulfonylurea or insulin), gallbladder disease (cholelithiasis / cholecystitis; class effect across the GLP-1 family).

⚠️ not listed on the WADA 2026 Prohibited List. Direct grep against the canonical WADA 2026 PDF confirms exenatide, GLP-1, and the related incretin-mimetic class are absent from the document — consistent with the entire GLP-1 ra family (Liraglutide, Semaglutide, Tirzepatide, Retatrutide) being absent from WADA listings.[⁶] Sixth negative-WADA-listing entry in the library (joining GHK-cu, PT-141, Liraglutide, Thymosin α1, Melanotan II). The GLP-1 receptor agonism mechanism does not fit any WADA prohibited category (S0–S9). Researchers competing in WADA-tested sport should still confirm against the current annual edition before competition; the absence of a current listing is not a guarantee of absence in future editions.

Quick reference

Compound class	39-amino-acid synthetic peptide; synthetic version of exendin-4 from Gila monster venom. GLP-1 receptor agonist. ~53% sequence homology with native GLP-1(7-36). DPP-4-resistant (substantially greater enzymatic stability than native GLP-1).
Common formulations (FDA-approved)	Byetta prefilled pen or per dose, twice daily SC. Bydureon single-dose tray powder + diluent, once weekly SC. Bydureon BCise single-dose autoinjector, once weekly SC. Bydureon Pen multi-dose pen, once weekly SC.
Off-label use	Not FDA-approved for obesity. Off-label weight-loss use exists but is uncommon — semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for the obesity indication and are the standard-of-care choices for that use case.
Frequency	Byetta: twice daily before meals. Bydureon: once weekly.
Half-life	Byetta: ~2.4 hours plasma half-life. Bydureon: ~7-day effective half-life via PLGA microsphere sustained-release (the parent peptide PK is unchanged; the formulation extends the dosing interval).
Route	Subcutaneous (both formulations).
Onset of action	Acute postprandial glucose-control effect within hours of Byetta dosing. Steady-state Bydureon levels reached within 6–7 weeks of weekly dosing. Clinical HbA1c response measurable within 12–14 weeks.

In depth

Exenatide is the synthetic version of exendin-4, a 39-amino-acid peptide isolated by Dr. John Eng in 1992 from the salivary gland venom of the Gila monster lizard (*Heloderma suspectum*).[⁴] The compound shares ~53% sequence homology with native human GLP-1(7-36) and acts as a GLP-1 receptor agonist — but with substantially greater enzymatic stability than native GLP-1, due to its resistance to cleavage by dipeptidyl peptidase-4 (DPP-4) at the N-terminal alanine position. Native GLP-1 has a half-life of minutes (rapidly cleaved by DPP-4); exenatide's modified N-terminus produces a half-life of hours (Byetta ~2.4 hours; Bydureon's effective half-life is days, controlled by the PLGA microsphere release profile).

The first FDA-approved GLP-1 receptor agonist. Amylin Pharmaceuticals (which had developed exenatide) partnered with Eli Lilly in 2002 to commercialize the compound. The pivotal AMIGO Phase 3 trial program (three 30-week trials in 1,400+ patients) established efficacy and safety of exenatide and BID as add-on therapy to metformin, sulfonylurea, or both in T2DM patients. Byetta received FDA approval on April 28, 2005, under NDA 021773 — the first incretin mimetic ever approved.[¹] This regulatory milestone opened the entire GLP-1 ra pharmaceutical category, which has subsequently expanded to include liraglutide (Victoza/Saxenda, FDA-approved 2010/2014), semaglutide (Ozempic 2017 / Wegovy 2021 / Rybelsus 2019), tirzepatide (Mounjaro 2022 / Zepbound 2023, dual GLP-1/GIP), and retatrutide (Phase 3, dual/triple agonist). All modern GLP-1 RAs derive their pharmaceutical-class genealogy from exenatide's 2005 approval.

Bydureon — extended-release reformulation. Amylin and Alkermes developed Bydureon (exenatide extended-release for injectable suspension) to address Byetta's twice-daily dosing burden and high nausea rate. Bydureon uses 50:50 poly(D,L-lactide-co-glycolide) (PLGA) microspheres ( per dose) along with sucrose ( per dose) to provide sustained release across the once-weekly dosing interval.[²] FDA approval was granted January 27, 2012, under NDA 022200 — the first and only once-weekly GLP-1 ra at the time of its approval. The DURATION clinical trial program supported the approval, with Bydureon producing improved glycemic control (HbA1c reduction) at once-weekly dosing and substantially reduced nausea vs Byetta. Subsequent FDA approvals: Bydureon BCise (autoinjector) 2017; Bydureon Pen (multi-dose pen) 2014; Bydureon BCise pediatric T2DM (≥10 years) 2021. The Bydureon product family was acquired by AstraZeneca through the Amylin acquisition.

EXSCEL cardiovascular outcomes trial (2017 NEJM). The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) was a pragmatic, randomized, double-blind, placebo-controlled event-driven trial assessing the long-term cardiovascular safety and efficacy of once-weekly exenatide. More than 14,500 patients enrolled at 687 sites across 35 countries, making it one of the largest GLP-1 ra cardiovascular outcomes trials. Primary endpoint (composite MACE): incidence did not differ significantly between exenatide and placebo (cardiovascular non-inferior).[³] Secondary endpoint: 14% lower incidence of all-cause mortality in exenatide-treated patients (prespecified secondary analysis). Holman et al. published the trial in *NEJM* in September 2017 (PMID 28910237). The EXSCEL trial established Bydureon's cardiovascular safety profile, supporting continued use even as semaglutide and tirzepatide displaced it commercially.

Modern positioning — substantially supplanted by semaglutide and tirzepatide. Exenatide's commercial position has declined dramatically since the launch of semaglutide (Ozempic 2017, Wegovy 2021) and tirzepatide (Mounjaro 2022, Zepbound 2023). Modern clinical practice in T2DM and obesity favors semaglutide or tirzepatide for several reasons: (a) Stronger HbA1c reduction: semaglutide produces ~1.5-2.0% HbA1c reduction vs ~0.8-1.0% for exenatide; tirzepatide produces ~2.0-2.5% reduction. (b) Stronger weight loss: tirzepatide (Zepbound) produces ~21% body weight loss vs exenatide's modest weight loss. (c) Better tolerability profile: semaglutide and tirzepatide have lower nausea rates than Byetta. (d) FDA-approved obesity indications: semaglutide and tirzepatide are FDA-approved for obesity; exenatide is not. (e) Cardiovascular outcomes: semaglutide (SUSTAIN-6) and dulaglutide (REWIND) showed cardiovascular benefit in MACE; exenatide (EXSCEL) showed non-inferiority but not superiority for the primary MACE endpoint. Exenatide remains useful for the regulatory-history anchor and for specific clinical contexts but is no longer the standard-of-care choice.

Regulatory status (US — current). Exenatide was FDA-approved as two distinct branded products (Byetta NDA 021773; Bydureon NDA 022200, with subsequent SUPPL approvals for the BCise autoinjector and the pediatric indication), but both are discontinued and their approvals were withdrawn — there is no currently-marketed branded exenatide. The FDA Orange Book lists BYETTA, BYDUREON, bydureon pen and bydureon bcise as discontinued; the only exenatide product listed as marketed is a generic twice-daily exenatide (Amneal, ANDA 206697). All FDA-approved indications are exclusively for T2DM — exenatide is not FDA-approved for obesity (which distinguishes it from Wegovy/semaglutide and Zepbound/tirzepatide). Not DEA-scheduled.

Regulatory status (sport — WADA). Not listed on the WADA 2026 Prohibited List — direct grep against the canonical 2026 PDF confirms exenatide and the broader GLP-1 family are absent.[⁶] Consistent with the entire incretin-mimetic class falling outside any WADA prohibited category. Sixth negative-WADA-listing entry in the library (joining GHK-cu, PT-141, Liraglutide, Thymosin α1, Melanotan II).

Common research interests. Despite the modern displacement by semaglutide/tirzepatide, exenatide remains relevant in research-community contexts for: - T2DM treatment — the FDA-approved use case. Clinical use under physician supervision. - Off-label weight-loss use — uncommon now that semaglutide and tirzepatide are FDA-approved for obesity. Legacy off-label exenatide weight-loss use exists but is increasingly rare. - Regulatory-history anchor — the foundational GLP-1 ra citation for the entire modern GLP-1 family. Researchers reading the GLP-1 family literature should be aware that exenatide is the parent compound. - Cardiovascular research — EXSCEL is one of the major GLP-1 ra cardiovascular outcomes trials and is cited extensively in the broader cardiovascular-diabetes literature.

Reported side effects

Commonly reported

Nausea — most common reported side effect. Substantially more common with Byetta (~40-50% of patients) than Bydureon (~10-20%). Usually subsides over first 4-8 weeks.
Vomiting — common; correlates with nausea
Diarrhea — common
Hypoglycemia — when combined with sulfonylurea or insulin
Injection site reactions — common; nodules at Bydureon injection sites are characteristic (PLGA microsphere depot)
Decreased appetite — common; mechanism of weight loss
Headache, dizziness — uncommon-to-moderate

Serious

Risk of thyroid C-cell tumors based on rat/mouse carcinogenicity data; contraindicated in patients with personal or family history of MTC or MEN 2.
Acute pancreatitis — class effect; case reports + theoretical concern. Discontinue if pancreatitis is suspected.
Acute kidney injury — particularly in patients with pre-existing renal impairment or volume depletion from GI side effects
Severe hypoglycemia — primarily when combined with sulfonylurea or insulin
Gallbladder disease (cholelithiasis, cholecystitis) — class effect across the GLP-1 family
Hypersensitivity reactions including anaphylaxis — uncommon
Severe injection site reactions including nodule formation, abscess, cellulitis — Bydureon-specific (PLGA microsphere related)

Contraindications and warnings

Personal or family history of medullary thyroid carcinoma (MTC)

Multiple endocrine neoplasia syndrome type 2 (MEN 2)

Hypersensitivity to exenatide or any product excipient

Type 1 diabetes or diabetic ketoacidosis — exenatide is not appropriate

Pancreatitis — discontinue if suspected; do not restart

Acute kidney injury — particular concern with severe renal impairment

Hypoglycemia — when combined with sulfonylurea or insulin

Gallbladder disease — class effect

Hypersensitivity reactions including anaphylaxis

Severe injection site reactions (Bydureon-specific)

Drug interactions affecting absorption — Byetta delays gastric emptying, which can affect oral medication absorption; consider timing relative to other oral drugs

Regulatory note (US): Exenatide's only FDA-approved indication was T2DM — as Byetta (twice daily, NDA 021773) and the Bydureon family (once weekly, NDA 022200). Both branded products are discontinued and their approvals withdrawn; the Orange Book lists only a generic twice-daily exenatide (Amneal, ANDA 206697) as marketed. Never FDA-approved for obesity. Standard prescription required (not DEA-scheduled).

Regulatory note (sport): Not listed on the WADA 2026 Prohibited List — confirmed by direct grep against the canonical 2026 PDF.[⁶] Sixth negative-WADA-listing entry in the library.

Not DEA-scheduled.

Key terms

GLP-1 receptor agonist: A compound that switches on the GLP-1 receptor, the same target a natural gut hormone uses to signal fullness and help regulate blood sugar.
Subcutaneous: An injection into the fatty layer just under the skin, rather than into a muscle or vein.
Half-life: Roughly how long the body takes to clear half of a dose. A long half-life is why some compounds can be taken only once a week.
Titration: Starting at a low dose and increasing it gradually.

Sources

Related entries

Amycretin — same mechanism class
CagriSema — same mechanism class
Dulaglutide — same mechanism class
Liraglutide — same mechanism class
Mazdutide — same mechanism class
Orforglipron — same mechanism class